Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PRO1184 |
| Synonyms | |
| Therapy Description |
PRO1184 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting FOLR1 linked to exatecan, which potentially inhibits growth of FOLR1-expressing tumors (Cancer Res 2022;82(12_Suppl):Abstract nr 1085). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PRO1184 | PRO-1184|PRO 1184|Rinatabart Sesutecan|Rina-S|GEN1184 | FOLR1-targeted Therapy 24 | PRO1184 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting FOLR1 linked to exatecan, which potentially inhibits growth of FOLR1-expressing tumors (Cancer Res 2022;82(12_Suppl):Abstract nr 1085). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05579366 | Phase Ib/II | Carboplatin + PRO1184 PRO1184 Bevacizumab + PRO1184 Pembrolizumab + PRO1184 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/PRO1184-001) (RAINFOL-01) | Recruiting | USA | 1 |
| NCT06619236 | Phase III | PRO1184 Gemcitabine Pegylated liposomal doxorubicin Paclitaxel Topotecan | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Recruiting | USA | POL | NOR | NLD | ITA | GRC | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | 2 |
CKB BOOST